Psychiatr. praxi. 2025;26(3):151-155 | DOI: 10.36290/psy.2025.025

Pharmacokinetic aspects of the second generation long acting injectable antipsychotics

MUDr. Martin Hýža, Ph.D.1, 2, MUDr. Tomáš Skřont1, 2
1 Psychiatrická klinika, Fakultní nemocnice Ostrava
2 Katedra klinických neurověd, Lékařská fakulta, Ostravská univerzita

Second generation long acting injectable antipsychotics supply gradually the portfolio of the agents available for the treatment of schizophrenia. The first preparation (risperidon microspheres) has been approved by FDA already in 2003, the last one (aripiprazol monohydrate once in two months) even in the last year. Compared to the first generation their great advantage is in better tolerability and the potential to improve affective symptoms among others. Recently new preparations with longer interval (2 or 3 months) have been introduced. Second generation LAI antipsychotics are characterized with more precisely defined pharmacokinetic profiles and mostly they don´t require p. o. supplementation. These properties shift the potential use towards earlier phases of treatment of psychotic episodes. Currently 6 types of atypical LAI antipsychotics are available which differ in technology of manufacturing. The presented article summarizes the characteristics of individual preparations.

Keywords: atypical antipsychotics, long acting injections, pharmacokinetics, schizophrenia, plasma levels.

Accepted: October 15, 2025; Published: November 6, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hýža M, Skřont T. Pharmacokinetic aspects of the second generation long acting injectable antipsychotics. Psychiatr. praxi. 2025;26(3):151-155. doi: 10.36290/psy.2025.025.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Purchase PDF - 60 CZK (2.5 EUR)
    will be unlocked 6.11.2026

    References

    1. Jann MW, Penzak SR. Long-Acting Injectable Second-Generation Antipsychotics: An Update and Comparison Between Agents. CNS Drugs. 2018;32(3):241-57. Go to original source... Go to PubMed...
    2. Evans EF, Proctor JD, Fratkin MJ, et al. Blood flow in muscle groups and drug absorption. Clin Pharmacol Ther. 1975;17(1):44-7. Go to original source... Go to PubMed...
    3. Wilson WH. A visual guide to expected blood levels of long-acting injectable risperidone in clinical practice. J Psychiatr Pract. 2004;10(6):393-401. Go to original source... Go to PubMed...
    4. Gharabawi GM, Gearhart NC, Lasser RA, et al. Maintenance therapy with once-monthly administration of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder: a pilot study of an extended dosing interval. Ann Gen Psychiatry. 2027;6(1):3. Dostupné z: https://doi.org/10.1186/1744-859X-6-3. Go to original source... Go to PubMed...
    5. Gefvert O, Eriksson B, Persson P, et al. Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia. Int J Neuropsychopharmacol. 2005;8(1):27-36. Go to original source... Go to PubMed...
    6. Lee LHN, Choi C, Collier AC, et al. The Pharmacokinetics of Second-Generation Long-Acting Injectable Antipsychotics: Limitations of Monograph Values. CNS Drugs. 2015;29(12):975-83. Go to original source... Go to PubMed...
    7. Correll CU, Kim E, Sliwa JK, et al. Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview. CNS Drugs. 2021;35(1):39-59. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7873121/. Go to original source... Go to PubMed...
    8. Haddad P, Lambert T, Lauriello J, editoři. Antipsychotic Long-acting Injections. 2nd edition. Oxford: Oxford University Press; 2016. 400 s. Go to original source...
    9. Meyer JM. Understanding depot antipsychotics: an illustrated guide to kinetics. CNS Spectr. prosinec 2013;18 Suppl 1:58-67; quiz 68. Go to original source... Go to PubMed...
    10. Eerdekens M, Van Hove I, Remmerie B, et al. Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia. Schizophr Res. 2004;70(1):91-100. Go to original source... Go to PubMed...
    11. Risperdal Consta, Souhrn údajů o přípravku, 2021.
    12. Cleton A, Rossenu S, Crauwels H, et al. A single-dose, open-label, parallel, randomized, dose-proportionality study of paliperidone after intramuscular injections of paliperidone palmitate in the deltoid or gluteal muscle in patients with schizophrenia. J Clin Pharmacol. 2014;54(9):1048-57. Go to original source... Go to PubMed...
    13. Rossenu S, Cleton A, Hough D, et al. Pharmacokinetic profile after multiple deltoid or gluteal intramuscular injections of paliperidone palmitate in patients with schizophrenia. Clin Pharmacol Drug Dev. 2015;4(4):270-8. Go to original source... Go to PubMed...
    14. Hough D, Lindenmayer JP, Gopal S, et al. Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(6):1022-31. Available from: https://www.sciencedirect.com/science/article/pii/S0278584609001663 Go to original source... Go to PubMed...
    15. Samtani MN, Vermeulen A, Stuyckens K. Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia: a novel once-monthly, long-acting formulation of an atypical antipsychotic. Clin Pharmacokinet. 2009;48(9):585-600. Go to original source... Go to PubMed...
    16. Xeplion, Souhrn údajů o přípravku, 2015.
    17. Citrome L. Long-acting injectable antipsychotics: what, when, and how. CNS Spectr. 2001;26(2):118-29. Available from: https://www.cambridge.org/core/journals/cns-spectrums/article/abs/longacting-injectable-antipsychotics-what-when-and-how/AF3C5EC823C1EF5938340613CD0C38FF. Go to original source...
    18. Schoretsanitis G, Spina E, Hiemke C, et al. A systematic review and combined analysis of therapeutic drug monitoring studies for oral paliperidone. Expert Rev Clin Pharmacol. 2018;11(6):625-39. Go to original source... Go to PubMed...
    19. Chue P, Chue J. A review of paliperidone palmitate. Expert Rev Neurother. 2012;12(12):1383-97. Available from: https://doi.org/10.1586/ern.12.137. Go to original source... Go to PubMed...
    20. Trevicta, Souhrn údajů o přípravku, 2014.
    21. Ravenstijn P, Remmerie B, Savitz A, et al. Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3-month formulation in patients with schizophrenia: A phase-1, single-dose, randomized, open-label study. J Clin Pharmacol. 2016;56(3):330-9. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/jcph.597. Go to original source... Go to PubMed...
    22. Heres S, Kraemer S, Bergstrom RF, et al. Pharmacokinetics of olanzapine long-acting injection: the clinical perspective. Int Clin Psychopharmacol. 2014;29(6):299-312. Go to original source... Go to PubMed...
    23. Bushe CJ, Falk D, Anand E, et al. Olanzapine long-acting injection: a review of first experiences of post-injection delirium/sedation syndrome in routine clinical practice. BMC Psychiatry. 2015;15(1):65. Available from: https://doi.org/10.1186/s12888-015-0450-9. Go to original source... Go to PubMed...
    24. ZypAdhera, Souhrn údajů o přípravku, 2013.
    25. Detke HC, Zhao F, Garhyan P, et al. Dose correspondence between olanzapine long-acting injection and oral olanzapine: recommendations for switching. Int Clin Psychopharmacol. 2011;26(1):35-42. Go to original source... Go to PubMed...
    26. Abilify Maintena, Souhrn údajů o přípravku, 2018.
    27. Mallikaarjun S, Kane JM, Bricmont P, et al. Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose study. Schizophr Res. 2013;150(1):281-8. Go to original source... Go to PubMed...
    28. Raoufinia A, Peters-Strickland T, Nylander AG, et al. Aripiprazole Once-Monthly 400 mg: Comparison of Pharmacokinetics, Tolerability, and Safety of Deltoid Versus Gluteal Administration. Int J Neuropsychopharmacol. 2017;20(4):295-304. Go to original source... Go to PubMed...
    29. Abilify Maintena, Souhrn údajů o přípravku, 2024.
    30. Wang Y, Harlin M, Larsen F, et al. Population Pharmacokinetics and Dosing Simulations for Aripiprazole 2-Month Ready-to-Use Long-Acting Injectable in Adult Patients With Schizophrenia or Bipolar I Disorder. Clin Pharmacol Drug Dev. 2024;13(6):631-43. Go to original source... Go to PubMed...
    31. Kopeček M, Masopust J. Dlouhodobě působící injekční intramuskulární aripiprazol aplikovaný jednou za 2 měsíce je připraven k použití. Psychiatr Časopis Mod Psychiatr. 2024;28(3):108-12.
    32. Mathews M, Gopal S, Singh A, et al. Comparison of Relapse Prevention with 3 Different Paliperidone Formulations in Patients with Schizophrenia Continuing versus Discontinuing Active Antipsychotic Treatment: A Post-Hoc Analysis of 3 Similarly Designed Randomized Studies. Neuropsychiatr Dis Treat. 2020;16:1533-42. Go to original source... Go to PubMed...
    33. Hýža M, Skřont T. Farmakokinetické aspekty léčby dlouhodobě působícími antipsychotiky a specifika preparátů 1. generace. Psychiatr. praxi. 2025;26(2):71-74. Go to original source...

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.